title: [WT1-targeting cancer vaccine].
abstract: Wilms' tumor gene WT1 encodes a transcription factor and functions as an oncogene. WT1 gene product WT1 protein is a promising par-tumor-associated antigen. WT1 peptide-based immunotherapy has been performing for more than six hundred patients with leukemias and various types of solid tumors. This immunotherapy is safe and has clinical benefit especially for leukemia, glioblastoma multiforme, advanced pancreatic cancer, and ovarian cancer. As a new strategy for cancer treatment, it should be recommended to initiate immunotherapy that had a potential of eradication of cancer stem cells before surgery, chemo- and radio-therapy.
authors.affiliation: Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine.
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
mesh_terms: D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D016896:Treatment Outcome; D025721:WT1 Proteins / Q000096:biosynthesis / Q000276:immunology*; D009396:Wilms Tumor / Q000235:genetics / Q000276:immunology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D025721:WT1 Proteins